Latest Europe News

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Aurora Labs reported a 15% revenue decline and a 12% increase in net loss for H1 2026, yet marked a strategic breakthrough with its first defence propulsion order and a successful $5.5 million capital raise.

PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.

Advanced Innergy Holdings Ltd (ASX:AIH) has reported a robust FY25 performance highlighted by a successful IPO and strong growth across its core segments, setting a confident tone for FY26.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Ramsay Health Care is set to simplify its corporate structure by distributing its majority stake in European healthcare provider Ramsay Santé directly to shareholders, enabling focused growth strategies for both entities.

Tungsten Mining has secured $53 million to push its Mt Mulgine Project through critical feasibility stages while engaging international partners for processing and offtake. The company is positioning itself as a key player in the global tungsten market with strategic moves in the US and Europe.

Little Green Pharma has entered a $7.8 million sale and leaseback agreement for its Western Australia production site, aiming to fuel growth in Australia and Europe while maintaining operational control.

Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.

Enero Group’s half-year results reveal a 6.3% revenue decline but a striking 119% surge in adjusted profit, alongside strategic leadership changes and a steady dividend.

Aristocrat Leisure reported robust FY25 results with double-digit revenue and profit growth, underpinned by strategic divestments and investments in AI. The company’s FY26 outlook remains positive, driven by market share gains and new product launches.